68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: Comparison with 111In-DTPA-octreotide (OctreoScan®)

Molecular Imaging and Biology

Volumn 13, Issue 3, 2011, Pages 583-593

  Krausz, Yodphat ^a   Freedman, Nanette ^a   Rubinstein, Rina ^a   Lavie, Efraim ^b   Orevi, Marina ^a   Tshori, Sagi ^a   Salmon, Asher ^a   Glaser, Benjamin ^a   Chisin, Roland ^a   Mishani, Eyal ^a   J Gross, David ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Radiopharmaceutical Division   (Israel)

Author keywords

111In DTPA octreotide; 68Ga DOTA NOC; Neuroendocrine tumors; PET CT

Indexed keywords

DOTA NOC GA 68; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 68GA TETRAAZACYCLODODECANE TETRAACETIC ACID NAL(3) OCTREOTIDE; 68GA-TETRAAZACYCLODODECANE TETRAACETIC ACID-NAL(3)-OCTREOTIDE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; ORGANOMETALLIC COMPOUND; SOMATOSTATIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CARCINOID; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MALE; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; RADIOGRAPHY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; SOMATOSTATIN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79956194831     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0374-1     Document Type: Article

References (22)

1. IM Modlin K Oberg DC Chung RT Jensen WW de Herder RV Thakker M Caplin G Delle Fave GA Kaltsas EP Krenning SF Moss O Nilsson G Rindi R Salazar P Ruszniewski A Sundin 2008 Gastroenteropancreatic neuroendocrine tumours Lancet Oncol 9 61 72 18177818 10.1016/S1470-2045(07)70410-2 1:CAS:528: DC%2BD1cXivVOltQ%3D%3D
2. K Oberg B Eriksson 2005 Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours Best Pract Res Clin Endocrinol Metab 19 265 276 15763700 10.1016/j.beem.2004.11.016 (Pubitemid 40347816)
3. DJ Kwekkeboom EP Krenning M de Jong 2000 Peptide receptor imaging and therapy J Nucl Med 41 1704 1713 11038002 1:CAS:528:DC%2BD3cXns1KmsLo%3D
4. G Kaltsas A Rockall D Papadogias R Reznek AB Grossman 2004 Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours Eur J Endocrinol 151 15 27 15248818 10.1530/eje.0.1510015 1:CAS:528:DC%2BD2cXmsFelur0%3D (Pubitemid 39117361)
5. S Froidevaux AN Eberle M Christe L Sumanovski A Heppeler JS Schmitt K Eisenwiener C Beglinger HR Mäcke 2002 Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model Int J Cancer 98 930 937 11948475 10.1002/ijc.10295 1:CAS:528: DC%2BD38Xis1OhurY%3D (Pubitemid 34286693)
6. P Antunes M Ginj H Zhang B Waser RP Baum JC Reubi H Maecke 2007 Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 34 982 993 17225119 10.1007/s00259-006-0317-x 1:CAS:528:DC%2BD2sXmtl2jtL8%3D (Pubitemid 46919547)
7. D Wild JS Schmitt M Ginj HR Mäcke BF Bernard E Krenning M De Jong S Wenger JC Reubi 2003 DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals Eur J Nucl Med Mol Imaging 30 1338 1347 12937948 10.1007/s00259-003-1255-5 1:CAS:528: DC%2BD3sXnslSntL8%3D (Pubitemid 37247950)
8. I Buchmann M Henze S Engelbrecht M Eisenhut A Runz M Schäfer T Schilling S Haufe T Herrmann U Haberkorn 2007 Comparison of (68)Ga-DOTATOC PET and (111)In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours Eur J Nucl Med Mol Imaging 34 1617 1626 17520251 10.1007/s00259-007-0450-1 1:STN:280:DC%2BD2srmtlaisQ%3D%3D (Pubitemid 47476920)
9. 68Ga-DOTA-Tyr3- Octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT J Nucl Med 48 508 518 17401086 10.2967/jnumed.106.035667 1:CAS:528:DC%2BD2sXhtVert7jF (Pubitemid 47571404)
10. 68Ga-DOTA-Tyr3-Octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy J Nucl Med 50 1427 1434 19690033 10.2967/jnumed.108.053421 1:CAS:528:DC%2BD1MXhtFOrtbrN
11. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience Nucl Med Commun 28 359 363 17414885 10.1097/MNM.0b013e32808ea0b0 (Pubitemid 46569168)
12. D Wild HR Mäcke B Waser JC Reubi M Ginj H Rasch J Müller-Brand M Hofmann 2005 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5 Eur J Nucl Med Mol Imaging 32 724 15551131 10.1007/s00259-004-1697-4 (Pubitemid 40897499)
13. C Pettinato A Sarnelli M Di Donna S Civollani C Nanni G Montini D Di Pierro M Ferrari M Marengo C Bergamini 2008 (68)Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors Eur J Nucl Med Mol Imaging 35 72 79 17874094 10.1007/s00259-007-0587-y 1:STN:280: DC%2BD2sjhs1KqsA%3D%3D (Pubitemid 350234154)
14. 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake J Nucl Med 40 762 767 10319747 1:CAS:528:DyaK1MXjsVamurw%3D (Pubitemid 29210749)
15. R Baum A Niesen J Leonhardi R Wortmann D Mueller F Roesch 2005 Receptor PET/CT imaging of neuroendocrine tumours using the Ga-68 labelled, high affinity somatostatin analogue DOTA-1-Nal3 Octreotide (DOTA-NOC): clinical results in 327 patients Eur J Nucl Med Mol Imaging 32 Suppl 1 54 55S (Abstract)
16. 68Ga-DOTA- NOC: a new PET tracer for evaluating patients with bronchial carcinoid Nucl Med Commun 30 281 286 19247211 10.1097/MNM.0b013e32832999c1
17. 68Ga-DOTA- NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours Eur J Nucl Med Mol Imaging 35 1431 1438 18418596 10.1007/s00259-008-0769-2 1:CAS:528:DC%2BD1cXovFyqur8%3D
18. 68Ga-DOTA-NOC PET Biomed Pharmacother 62 667 671 18358680 10.1016/j.biopha.2008.01.010 1:CAS:528:DC%2BD1cXhtlyksL3K
19. V Prasad V Ambrosini M Hommann D Hoersch S Fanti RP Baum 2010 Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT Eur J Nucl Med Mol Imaging 37 67 77 19618183 10.1007/s00259-009-1205-y 1:CAS:528:DC%2BD1MXhsFCktLrF
20. KR Zasadny RL Wahl 1993 Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction Radiology 189 847 850 8234714 1:STN:280: DyaK2c%2Flt1Kiug%3D%3D (Pubitemid 23354506)
21. 177Lu DOTA-NOC Cancer Biother Radiopharm 22 406 416 17651048 10.1089/cbr.2006.325 1:CAS:528: DC%2BD2sXotFygsbg%3D (Pubitemid 47067899)
22. 68Ga for medical application J Nucl Med 48 1741 1748 17873136 10.2967/jnumed.107.040378 1:CAS:528:DC%2BD2sXht1GlurnE (Pubitemid 47572722)